These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26644449)

  • 21. Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).
    Finke LH; Wentworth K; Blumenstein B; Rudolph NS; Levitsky H; Hoos A
    Vaccine; 2007 Sep; 25 Suppl 2():B97-B109. PubMed ID: 17916465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Critical issues in cancer vaccine trial design.
    Clifton GT; Kohrt HE; Peoples GE
    Vaccine; 2015 Dec; 33(51):7386-7392. PubMed ID: 26392010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer immunotherapy: Breakthrough or "deja vu, all over again"?
    Sell S
    Tumour Biol; 2017 Jun; 39(6):1010428317707764. PubMed ID: 28639883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer vaccines: between the idea and the reality.
    Finn OJ
    Nat Rev Immunol; 2003 Aug; 3(8):630-41. PubMed ID: 12974478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy is different: Implications for vaccine clinical trial design.
    Simon R
    Hum Vaccin Immunother; 2017 Sep; 13(9):2179-2184. PubMed ID: 28498733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Combination of Targeted Therapy and Immunotherapy for Cancer].
    Kadowaki N
    Gan To Kagaku Ryoho; 2015 Sep; 42(9):1046-9. PubMed ID: 26469160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].
    Ikeda H; Shiku H
    Nihon Rinsho; 2012 Dec; 70(12):2043-50. PubMed ID: 23259373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Oncoimmunology: some fundamental problems of cancer immunotherapy].
    Nedospasov SA; Kuprash DV
    Mol Biol (Mosk); 2007; 41(2):355-68. PubMed ID: 17514902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic cancer vaccines: a long and winding road to success.
    Baxevanis CN; Papamichail M; Perez SA
    Expert Rev Vaccines; 2014 Jan; 13(1):131-44. PubMed ID: 24224539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy.
    Schreurs MW; Eggert AA; Punt CJ; Figdor CG; Adema GJ
    Crit Rev Oncog; 2000; 11(1):1-17. PubMed ID: 10795625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy].
    Van den Eynde B
    Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-13 receptor-directed cancer vaccines and immunotherapy.
    Nakashima H; Husain SR; Puri RK
    Immunotherapy; 2012 Apr; 4(4):443-51. PubMed ID: 22512637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New frontiers in cell-based immunotherapy of cancer.
    D'Elios MM; Del Prete G; Amedei A
    Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic immune restraints: implications for anticancer vaccines.
    Mocellin S
    Curr Pharm Des; 2010 Jan; 16(3):277-91. PubMed ID: 20109137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cell immunotherapy for the treatment of neoplastic disease.
    Decker WK; Xing D; Shpall EJ
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies.
    Dalgleish AG
    Vaccine; 2011 Nov; 29(47):8501-5. PubMed ID: 21933695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell fusion: from hybridoma to dendritic cell-based vaccine.
    Gong J; Koido S; Calderwood SK
    Expert Rev Vaccines; 2008 Sep; 7(7):1055-68. PubMed ID: 18767954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanomedicine and cancer immunotherapy - targeting immunosuppressive cells.
    Torres Andón F; Alonso MJ
    J Drug Target; 2015; 23(7-8):656-71. PubMed ID: 26453162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
    Moschella F; Proietti E; Capone I; Belardelli F
    Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.